Page last updated: 2024-12-05

ethamsylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ethamsylate, also known as D-ethyl-3-amino-4-hydroxy-6-methyl-2-pyridine-carboxylate, is a synthetic derivative of nicotinic acid. It is a vasoconstrictor agent that is used to treat a variety of conditions including capillary fragility, epistaxis (nosebleeds), and menorrhagia (heavy menstrual bleeding). The mechanism of action of ethamsylate is not fully understood, but it is thought to work by increasing the resistance of capillaries to breakage, thereby reducing bleeding. Ethamsylate has been used for several decades, and it is available in a variety of countries worldwide. It is typically administered orally, but it can also be given intravenously or intramuscularly. Ethamsylate is generally well-tolerated, but side effects can include nausea, vomiting, diarrhea, and headache. Ethamsylate is a relatively inexpensive and effective treatment for capillary fragility and other conditions. It is widely used in many countries, and it is often considered a first-line treatment for these conditions.'

Ethamsylate: Benzenesulfonate derivative used as a systemic hemostatic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID17506
CHEMBL ID1514715
CHEBI ID31563
SCHEMBL ID34303
MeSH IDM0007819

Synonyms (89)

Synonym
einecs 220-090-7
altodor
diethylammonium 2,5-dihydroxybenzenesulfonate
etamsilato [inn-spanish]
ciclonamina [italian]
e 141
dicynene
diethylammonium cyclohexadien-4-ol-1-one-4-sulfonate
dicynone
diidroxi-1,4-benzenesulfonato-3-di-etilammonium [italian]
cyclonamine
md 141
etamsylate
eselin
2,5-dihydroxybenzenesulfonic acid compound with diethylamine (1:1)
aglumin
etamsylatum [inn-latin]
NCGC00017041-01
cas-2624-44-4
ethamsylate
etamsylate (jan/inn)
2624-44-4
ethamsylate (usan)
D01282
NCGC00017041-02
FT-0668047
HMS1571K11
AKOS005267176
HMS2098K11
ciclonamina
unii-24yl531voh
diidroxi-1,4-benzenesulfonato-3-di-etilammonium
ethamsylate [usan]
etamsilato
etamsylate [inn]
etamsylatum
24yl531voh ,
2,5-dihydroxybenzenesulfonic acid n-ethylethanamine (1:1)
tox21_110752
dtxcid2025559
dtxsid4045559 ,
S4152
c18e8
e-141
etamsylate [ep monograph]
etamsylate [jan]
md-141
etamsilate [who-dd]
diethylamine dobesilate
etamsylate [mart.]
etamsilate
ethamsylate [mi]
2,5-dihydroxybenzenesulfonic acid n-ethylethanamine
CCG-221015
SCHEMBL34303
KS-1169
CS-4630
HBGOLJKPSFNJSD-UHFFFAOYSA-N
diethylamine 2,5-dihydroxy benzene sulfonate
NCGC00017041-04
W-107184
CHEMBL1514715
HY-B1074
E1145
diethylamine 2,5-dihydroxybenzenesulfonate
SR-01000838306-2
sr-01000838306
HMS3652I22
AC-32031
CHEBI:31563
HMS3715K11
SW197271-3
F20533
DB13483
mfcd00867499
etamsylate,(s)
BCP12254
Q2000876
AMY8982
A847477
2,5-dihydroxybenzenesulfonic acid;n-ethylethanamine
etamsylate 100 microg/ml in acetonitrile
2,5-dihydroxybenzenesulfonic acid n-ethylethanamine salt
2,5-dihydroxybenzene- sulfonic acid diethylamine salt
etamsilato (inn-spanish)
etamsylate (ep monograph)
b02bx01
etamsylate (mart.)
etamsylatum (inn-latin)

Research Excerpts

Overview

Ethamsylate was shown to be an effective anti-inflammatory agent with a time course and amplitude of effect similar to that of indomethacin, although the potency was only about 4% of that for indomet hacin.

ExcerptReferenceRelevance
"2. Ethamsylate was shown to be an effective anti-inflammatory agent with a time course and amplitude of effect similar to that of indomethacin, although the potency was only about 4% of that for indomethacin."( Effect of ethamsylate on carrageenan-induced rat paw oedema: a comparison with indomethacin.
Gard, PR; Trigger, DJ, 1990
)
1.2

Effects

Ethamsylate has been used with good results to decrease bleeding in various pathologies such as metrorrhagia, intraventricular bleeding, prostatectomies, cataract surgeries and tonsillectomies.

ExcerptReferenceRelevance
"Ethamsylate has been used with good results to decrease bleeding in various pathologies such as metrorrhagia, intraventricular bleeding, prostatectomies, cataract surgeries and tonsillectomies."( [Uso de etamsilato para reducir el sangrado posoperatorio y el índice de transfusión en la artroplastia total de cadera. Ensayo clínico controlado].
Blázquez-Saldaña, J; Morales-Avalos, R; Peña-Martínez, VM; Ramos-Morales, T; Ramos-Sánchez, TA; Vílchez-Cavazos, F, 2018
)
1.2
"Ethamsylate, which has been useful in primary menor rhagia, is undergoing evaluation."( Letter: Alleviation of IUD menorrhagia with ethamsylate.
Campbell, S; Harrison, RF, 1976
)
1.14

Pharmacokinetics

ExcerptReferenceRelevance
" The aim of the research was to be able to provide detection time (DT) advice from pharmacokinetic (PK) studies in Thoroughbred horses to better inform trainers, and their veterinary surgeons, prescribing these substances for treatment of Thoroughbred racehorses."( Novel holistic pharmacokinetic model applied to plasma and urine concentrations of 2,5-dihydroxybenzene sulphonate following administrations of calcium dobesilate and etamsylate to exercised horses.
Habershon Butcher, J; Harding, C; Hincks, PR; Paine, SW; Viljanto, M; Waller, CC; Zemenova, J, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"In a bid to minimise dosage and possible side-effects when relieving post episiotomy pain, the NSAID Indomethacin was studied in combination with a systemic haemostat Ethamsylate which has been shown to selectively inhibit some prostaglandins."( Indomethacin and ethamsylate alone and in combination for the relief of post episiotomy pain.
Devitt, M; Harrison, RF, 1992
)
0.82
" The method was applied for the determination of the studied drugs in different dosage forms and biological fluids."( Simultaneous determination of some dihydroxybenzenesulphonic acid derivatives and their degradation product and main impurity (hydroquinone) by ion-pair liquid chromatography.
Tolba, MM, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (2 Product(s))

Product Categories

Product CategoryProducts
Herbs, Botanicals & Homeopathy1
Vitamins & Supplements1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Sinupret Bionorica Sinupret Adult Strength -- 50 TabletsSinupretHerbs, Botanicals & Homeopathydextrin, E141, eudragit E12.5, Calcium carbonate, riboflavin, stearic acid, titanium dioxide2024-11-29 10:47:42
Sinupret Plus for Adults -- 25 TabletsSinupretVitamins & SupplementsE 141, E 132, Calcium carbonate, E 1712024-11-29 10:47:42

Drug Classes (2)

ClassDescription
sulfonic acid derivative
organosulfur compoundAn organosulfur compound is a compound containing at least one carbon-sulfur bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency5.12560.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency5.12560.025120.237639.8107AID886; AID893
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency0.39810.00137.762544.6684AID914; AID915
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency18.99910.01237.983543.2770AID1645841
estrogen nuclear receptor alphaHomo sapiens (human)Potency1.14430.000229.305416,493.5996AID743075
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency7.07950.10009.191631.6228AID1346983
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency14.12540.001815.663839.8107AID894
lamin isoform A-delta10Homo sapiens (human)Potency0.14130.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1365098Inhibition of ADP-induced platelet aggregation in human plasma2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
Synthesis and biological evaluation of a new series of cinnamic acid amide derivatives as potent haemostatic agents containing a 2-aminothiazole substructure.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (184)

TimeframeStudies, This Drug (%)All Drugs %
pre-199073 (39.67)18.7374
1990's33 (17.93)18.2507
2000's28 (15.22)29.6817
2010's40 (21.74)24.3611
2020's10 (5.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 71.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index71.86 (24.57)
Research Supply Index5.61 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index124.19 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (71.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials62 (29.67%)5.53%
Reviews22 (10.53%)6.00%
Case Studies11 (5.26%)4.05%
Observational0 (0.00%)0.25%
Other114 (54.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparative Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate to Reduce Blood Loss Intraoperative and Post Operative During Elective Cesarean Section [NCT04656067]Phase 1/Phase 2230 participants (Actual)Interventional2020-04-01Completed
Tranexamic Acid and Ethamsylate For Preventing Post Partum Hemorrhage in Patient Undergoing LSCS at High Risk For Post PartumHemorrhage : A Randomized Controlled Trial [NCT02604719]Phase 1/Phase 264 participants (Anticipated)Interventional2015-11-30Not yet recruiting
Comparing the Effectiveness of Misoprostol, Oxytocin, Carbetocin, Vasopressin, Bupivacaine and Epinephrine, Combined IV TXA Acid and Ethamsylate and Peri Cervical Tourniquet for the Reduction of Blood Loss During of Abdominal Myomectomy. [NCT05806307]Phase 4105 participants (Anticipated)Interventional2023-03-15Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]